Neurocrine Biosciences Revenue and Competitors

Claim your profile



Total Funding



Estimated Revenue & Valuation

  • Neurocrine Biosciences's estimated annual revenue is currently $1.1B per year.(i)
  • Neurocrine Biosciences's estimated revenue per employee is $839,216
  • Neurocrine Biosciences's total funding is $10M.

Employee Data

  • Neurocrine Biosciences has 1275 Employees.(i)
  • Neurocrine Biosciences grew their employee count by 25% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation

Neurocrine Biosciences, Inc. is a product-based biopharmaceutical company focused on neurologic and endocrine diseases and disorders. The Company's product candidates address pharmaceutical markets such as insomnia, anxiety, depression, cancer and diabetes. The Company's product candidates include gamma amino-butyric acid (GABA)-A Agonist, Corticotropin-Releasing Factor, IL-4 Fusion Toxin, Altered Peptide Ligands and Gonadotropin-Releasing Hormone Receptor.



Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Neurocrine Biosciences News

2022-04-20 - Neurocrine Biosciences (NBIX) Shares Cross Below 200 DMA

In trading on Thursday, shares of Neurocrine Biosciences, Inc. (Symbol: NBIX) crossed below their 200 day moving average of $90.72,...

2022-04-19 - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Forecasted to ...

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Forecasted to Earn Q1 2022 Earnings of $0.45 Per Share. Posted by admin on Apr 27th, 2022.

2022-03-30 - Neurocrine Biosciences inks deal for new, 535,000-square-foot headquarters campus in Carmel Valley

Founded in 1992, Neurocrine is one of San Diego's largest therapeutics firms, with 900 employees and a $9.3 billion market value. It has four...

2021-08-05 - Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease

SAN DIEGO, Aug. 5, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), in collaboration with the Huntington Study Group, today announced the completion of patient enrollment for its Phase 3 (KINECT-HD) clinical study evaluating the efficacy, safety and tolerability of valbenazine ...

2021-07-19 - Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2021 Financial Results

SAN DIEGO, July 19, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter 2021 financial results after the Nasdaq market closes on Tuesday, August 3, 2021. Neurocrine will then host a conference call and webcast to discuss its finan ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding